EXACT Therapeutics (EXTX) DNB Carnegie Nordic Healthcare Conference Presentation summary

Strategic focus and technology

• Developing ultrasound-mediated Acoustic Cluster Therapy (ACT) to enhance drug delivery in solid tumors, with a primary focus on oncology.

• ACT is a noninvasive platform enabling targeted, organ-specific drug delivery, administered alongside standard therapeutics.

• Proprietary compound PS101 demonstrated clinical proof-of-concept in Phase 1, showing a 4x increase in tumor shrinkage versus standard of care in liver metastases.

• Broad intellectual property coverage across major markets and multiple use cases.

• Raised $13 million in December 2024, with GE Healthcare as anchor investor.

Clinical pipeline and milestones

• Ongoing Phase 2 ENACT trial in first-line locally advanced pancreatic cancer, with interim readout expected 1H 2026 and final readout in 1H 2027.

• ACTIVATE Phase 1 trial in liver metastases showed ACT-treated tumors had a -29% reduction in diameter versus -7% for controls, with excellent safety profile.

• Preclinical and research collaborations in immuno-oncology and CNS cancers, including glioblastoma and blood-brain barrier models.

• Major 2025 milestones include final ACTIVATE results, regulatory approvals, and initial safety data from ENACT.

Market opportunity and industry context

• Pancreatic cancer remains a high-need area with low survival rates and limited FDA-approved treatments.

• Therapeutic ultrasound sector is attracting significant investment, with recent large financings and acquisitions.

• Leading medical equipment company is a vested device and supply partner.